Citigroup
TCON

Citigroup’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Citigroup’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4
Closed -$12K – 7807
2015
Q1 		$12K Buy
+4
New +$10.5K ﹤0.01% 6385

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $18.3B AUM 27.14% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citigroup's TCON Position: Q2 2015 in Review

Citigroup sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2015, closing a stake of 4 shares — an estimated $12K sold.

Citigroup first reported a position in TCON in Q1 2015 and held it in 1 quarter. The position peaked at $12K in Q1 2015. 20 funds tracked by Wall St. Rank hold TCON as of Q2 2015.

  • Citigroup reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Citigroup sold 4 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2015, an estimated $12K.
  • Citigroup first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Citigroup's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $12K in Q1 2015.
  • 20 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2015.

Based on Citigroup's 13F filing for Q2 2015, filed 13 Aug 2015.